

CITATION REPORT

List of articles citing

No Influence of the MDR-1 C3435T Polymorphism or a CYP3A4 Promoter Polymorphism (CYP3A4-V Allele) on Dose-adjusted Cyclosporin A Trough Concentrations or Rejection Incidence in Stable Renal Transplant Recipients

DOI: 10.1093/clinchem/47.6.1048
Clinical Chemistry, 2001, 47, 1048-1052.

Source: <https://exaly.com/paper-pdf/32636375/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
255	The MDR1 C3435T polymorphism: effects on P-glycoprotein expression/function and clinical significance. 2001 , 3, 4-6		8
254	Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. 2002 , 302, 804-13		287
253	MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences. 2002 , 12, 425-7		74
252	Two-hour cyclosporine concentration determination: an appropriate tool to monitor neoral therapy?. <i>Therapeutic Drug Monitoring</i> , 2002 , 24, 40-6	3.2	73
251	Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. 2002 , 74, 1486-9		251
250	Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. 2002 , 12, 437-50		252
249	C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. 2002 , 12, 451-7		175
248	MDR1 genotype-related pharmacokinetics and pharmacodynamics. 2002 , 25, 1391-400		148
247	Drug interactions with tacrolimus. 2002 , 25, 707-12		87
246	Detection of MDR1 single nucleotide polymorphisms C3435T and G2677T using real-time polymerase chain reaction: MDR1 single nucleotide polymorphism genotyping assay. 2002 , 4, E29		16
245	Genetic defects in hepatobiliary transport. 2002 , 1586, 129-45		92
244	The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. 2002 , 63, 765-70		90
243	Basal expression of the multidrug resistance gene 1 (MDR-1) is associated with the TT genotype at the polymorphic site C3435T in mammary and ovarian carcinoma cell lines. 2002 , 185, 79-85		25
242	The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans. <i>Advanced Drug Delivery Reviews</i> , 2002 , 54, 1295-310	18.5	206
241	Genetic contribution to variable human CYP3A-mediated metabolism. <i>Advanced Drug Delivery Reviews</i> , 2002 , 54, 1271-94	18.5	764
240	Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. 2002 , 19, 1581-5		93
239	Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. 2002 , 72, 209-19		264

238	The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. 2002 , 72, 572-83		161
237	Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. 2002 , 72, 584-94		243
236	Quantitative evaluation of the function of small intestinal P-glycoprotein: comparative studies between in situ and in vitro. 2003 , 20, 1163-9		62
235	Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. 2003 , 74, 245-54		501
234	Genetic polymorphisms of the human MDR1 drug transporter. 2003 , 43, 285-307		265
233	Arzneimitteltransporter. 2003 , 44, 219-226		1
232	Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. 2003 , 3, 477-83		206
231	Detection of the four sequence variations of MDR1 gene using TaqMan MGB probe based real-time PCR and haplotype analysis in healthy Japanese subjects. 2003 , 36, 511-8		39
230	No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects. 2003 , 74, 487-98		45
229	Quantitative determination of MDR1 mRNA expression in peripheral blood lymphocytes: a possible role of genetic polymorphisms in the MDR1 gene. 2003 , 33, 261-7		42
228	P-glycoprotein: from genomics to mechanism. 2003 , 22, 7468-85		847
227	Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. <i>Pharmacogenomics</i> , 2003 , 4, 397-410	2.6	186
226	Role of P-glycoprotein in pharmacokinetics: clinical implications. <i>Clinical Pharmacokinetics</i> , 2003 , 42, 59-98		593
225	Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. 2003 , 6, 71-84		181
224	The pharmacogenetics of immunosuppression for organ transplantation: a route to individualization of drug administration. 2003 , 3, 291-301		26
223	CYP3A4 and MDR1 alleles in a Portuguese population. 2003 , 41, 1345-50		33
222	Measurement of beta1- and beta2-globulins improves detection of M-spikes on high-resolution electrophoresis. <i>Clinical Chemistry</i> , 2003 , 49, 676-8	5.5	9
221	Genetic basis of psoriasis vulgaris and its pharmacogenetic potential. <i>Pharmacogenomics</i> , 2003 , 4, 297-308		5

220	The Effect of CYP3A5 and MDR1 Polymorphic Expression on Cyclosporine Oral Disposition in Renal Transplant Patients. <i>Journal of Clinical Pharmacology</i> , 2003 , 43, 555-564	2.9	109
219	Simultaneous genotyping of seven single-nucleotide polymorphisms in the MDR1 gene by single-tube multiplex minisequencing. <i>Clinical Chemistry</i> , 2003 , 49, 672-6	5.5	26
218	Cholestasis. 2003 , 52 Suppl 2, ii42-8		17
217	Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. 2003 , 14, 1889-96		235
216	Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. 2003 , 22, 1117		3
215	Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. 2003 , 13, 661-74		74
214	Pharmacogenomics of immunosuppressive drug metabolism. 2003 , 12, 607-13		22
213	MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients. <i>Journal of Clinical Pharmacology</i> , 2003 , 43, 1101-7	2.9	55
212	Pharmacogenomics of Bioavailability and Elimination. 2003 , 363-380		
211	[MDR1 genotypes related to pharmacokinetics and MDR1 expression]. 2003 , 123, 773-9		7
210	. 2003 ,		18
209	Pharmacogenetics of the Human MDR1 Multidrug Transporter. 2004 , 2, 1-11		7
208	The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. <i>Current Drug Metabolism</i> , 2004 , 5, 11-9	3.5	98
207	Pharmacogenetics of drug transporters and its impact on the pharmacotherapy. 2004 , 4, 1385-98		74
206	Factors affecting cytochrome P-450 3A activity in cancer patients. 2004 , 10, 8341-50		107
205	MDR1 haplotypes modify BEN disease risk: a study in Bulgarian patients with Balkan endemic nephropathy compared to healthy controls. 2004 , 96, e7-13		17
204	Pharmacogenomics of MDR1/ABCB1 gene: the influence on risk and clinical outcome of haematological malignancies. 2004 , 9, 91-105		62
203	Multidrug resistance gene G1199A polymorphism alters efflux transport activity of P-glycoprotein. 2004 , 310, 1199-207		72

202	The genetic polymorphism of drug transporters: functional analysis approaches. <i>Pharmacogenomics</i> , 2004 , 5, 67-99	2.6	70
201	Functional evaluation of ABCB1 (P-glycoprotein) polymorphisms: high-speed screening and structure-activity relationship analyses. 2004 , 19, 1-14		63
200	The impact of pharmacogenomic factors on steroid dependency in pediatric heart transplant patients using logistic regression analysis. <i>Pediatric Transplantation</i> , 2004 , 8, 551-7	1.8	34
199	From pharmacokinetics to pharmacogenomics: a new approach to tailor immunosuppressive therapy. 2004 , 4, 299-310		49
198	The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation. 2004 , 4, 914-9		211
197	Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia. 2004 , 72, 314-21		154
196	Pharmacogenetics of disease-modifying anti-rheumatic drugs. 2004 , 18, 233-47		33
195	Functional implications of genetic polymorphisms in the multidrug resistance gene MDR1 (ABCB1). 2004 , 21, 904-13		91
194	Genetic polymorphisms and prostate cancer risk. 2004 , 21, 414-23		45
193	Cytochrome P450 3A and their regulation. 2004 , 369, 105-24		103
192	Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. 2004 , 75, 13-33		659
191	CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. 2004 , 75, 422-33		150
190	Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes. 2004 , 76, 545-56		128
189	The MDR1 (ABCB1) gene polymorphism and its clinical implications. <i>Clinical Pharmacokinetics</i> , 2004 , 43, 553-76	6.2	113
188	Pharmacogenetics and pharmacogenomics of immunosuppressive agents: perspective for individualized therapy. 2004 , 1, 53-62		1
187	MDR-1 C3435T polymorphism influences cyclosporine a dose requirement in liver-transplant recipients. 2004 , 78, 21-5		64
186	Pharmacogenetics in solid organ transplantation: present knowledge and future perspectives. 2004 , 78, 311-5		38
185	Pharmacogenomics of MDR and MRP subfamilies. 2004 , 1, 85-104		18

184	Whole-blood cultures from renal-transplant patients stimulated ex vivo show that the effects of cyclosporine on lymphocyte proliferation are related to P-glycoprotein expression. 2004 , 77, 557-61		17
183	CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. 2004 , 14, 471-8		162
182	Pharmacogenetics in immunosuppressive therapy: the best thing since TDM?. <i>Therapeutic Drug Monitoring</i> , 2004 , 26, 343-6	3.2	12
181	The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. 2004 , 14, 147-54		368
180	Clinical aspects of the MDR1 (ABCB1) gene polymorphism. <i>Therapeutic Drug Monitoring</i> , 2004 , 26, 180-5	3.2	165
179	Pharmacogenomics of drug transporters: a new approach to functional analysis of the genetic polymorphisms of ABCB1 (P-glycoprotein/MDR1). 2004 , 27, 939-48		45
178	Host determinants of antiretroviral drug activity. 2005 , 18, 543-9		13
177	MDR1 genetic polymorphisms and comparison of MDR1 haplotype profiles in Korean and Vietnamese populations. <i>Therapeutic Drug Monitoring</i> , 2005 , 27, 531-5	3.2	35
176	Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. 2005 , 80, 977-84		89
175	Seeking optimal prescription of cyclosporine ME. <i>Therapeutic Drug Monitoring</i> , 2005 , 27, 3-6	3.2	9
174	Lack of association of CYP3A4-V polymorphism with the risk of treatment-related leukemia. 2005 , 29, 595-7		9
173	Genetic polymorphisms of cytochrome P450 among patients with Balkan endemic nephropathy (BEN). 2005 , 38, 223-8		45
172	Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. 2005 , 78, 559-81		96
171	Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2. <i>Pharmacogenomics</i> , 2005 , 6, 115-38	2.6	100
170	Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. 2005 , 46, 643-7		176
169	Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients. <i>British Journal of Clinical Pharmacology</i> , 2005 , 59, 18-27	3.8	21
168	Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. <i>British Journal of Clinical Pharmacology</i> , 2005 , 60, 159-71	3.8	105
167	Consequences of genetic polymorphisms for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. 2005 , 5, 595-603		116

166	Pharmacokinetic principles of immunosuppressive drugs. 2005 , 5, 207-17		53
165	Pharmacogenetics and rheumatology: Molecular mechanisms contributing to variability in drug response. 2005 , 52, 1349-59		5
164	Pharmacokinetics and neutrophil toxicity of paclitaxel orally administered in mice with recombinant interleukin-2. 2005 , 55, 61-71		3
163	MDR1 genotype-related pharmacokinetics: fact or fiction?. 2005 , 20, 391-414		117
162	An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore. 2005 , 37, 327-78		86
161	Cytochrome P450 3A polymorphisms and immunosuppressive drugs. <i>Pharmacogenomics</i> , 2005 , 6, 37-47	2.6	44
160	The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression?. <i>Pharmacogenomics</i> , 2005 , 6, 323-37	2.6	76
159	ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. 2005 , 16, 1501-11		186
158	Pharmakogenetik. 2005 , 153, 741-750		1
157	Does pharmacogenetics have the potential to allow the individualisation of immunosuppressive drug dosing in organ transplantation?. 2005 , 6, 2593-605		6
156	Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCG2: therapeutic implications. 2005 , 6, 2455-73		27
155	Pharmacogenetic differences and drug-drug interactions in immunosuppressive therapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2005 , 1, 487-503	5.5	15
154	The impact of pharmacogenomic factors on acute persistent rejection in adult lung transplant patients. 2005 , 14, 37-42		39
153	Clinical pharmacogenetics of immunosuppressive drugs in organ transplantation. <i>Pharmacogenomics</i> , 2005 , 6, 163-8	2.6	21
152	Occupational exposure to polycyclic aromatic hydrocarbons in German industries: association between exogenous exposure and urinary metabolites and its modulation by enzyme polymorphisms. 2005 , 157, 241-55		56
151	Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms. 2005 , 75, 21-6		57
150	Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokinetics. <i>Journal of Clinical Pharmacology</i> , 2005 , 45, 411-21	2.9	14
149	Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population. <i>Molecular Diagnosis and Therapy</i> , 2006 , 10, 175-85	4.5	27

148	Clinical implications of CYP3A polymorphisms. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2006 , 2, 171-82	5.5	94
147	Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2006 , 2, 651-74	5.5	42
146	The ATP-binding cassette transporters and their implication in drug disposition: a special look at the heart. 2006 , 58, 244-58		88
145	Genetic testing for pharmacogenetics and its clinical application in drug therapy. <i>Clinica Chimica Acta</i> , 2006 , 363, 177-86	6.2	33
144	Down-regulation of ABCB1 transporter by atorvastatin in a human hepatoma cell line and in human peripheral blood mononuclear cells. 2006 , 1760, 1866-73		29
143	Implications of genetic polymorphisms in drug transporters for pharmacotherapy. 2006 , 234, 4-33		190
142	MDR1 C3435T polymorphisms correlate with cyclosporine levels in de novo renal recipients. <i>Transplantation Proceedings</i> , 2006 , 38, 2847-9	1.1	26
141	Overview of pharmacogenetics. 2006 , Chapter 9, Unit 9.19		1
140	The MDR1/ABCB1 gene, a high-impact risk factor for cardiac transplant rejection. 2006 , 82, 1677-82		19
139	Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition. <i>Journal of Clinical Pharmacology</i> , 2006 , 46, 515-26	2.9	8
138	Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients. <i>Pharmacogenetics and Genomics</i> , 2006 , 16, 659-65	1.9	91
137	Pharmacogenetics in transplant patients: can it predict pharmacokinetics and pharmacodynamics?. <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 23-30	3.2	31
136	Impact of citrus soft drinks relative to grapefruit juice on ciclosporin disposition. <i>British Journal of Clinical Pharmacology</i> , 2006 , 62, 485-91	3.8	20
135	The effect of CYP2J2, CYP3A4, CYP3A5 and the MDR1 polymorphisms and gender on the urinary excretion of the metabolites of the H-receptor antihistamine ebastine: a pilot study. <i>British Journal of Clinical Pharmacology</i> , 2006 , 62, 177-86	3.8	20
134	Pharmacogenomics and lung transplantation: clinical implications. 2006 , 6, 301-10		11
133	Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients. 2006 , 79, 90-102		39
132	Pharmacogenomics and individualized drug therapy. 2006 , 57, 119-37		486
131	Prediction of systemic exposure to cyclosporine in Japanese pediatric patients. 2006 , 51, 969-976		8

130	An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. 2006 , 112, 184-98			151
129	Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. 2006 , 112, 457-73			274
128	Adenosine triphosphate-binding cassette B1 (ABCB1) (multidrug resistance 1) G2677T/A gene polymorphism is associated with high risk of lung cancer. 2006 , 107, 2850-7			50
127	Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in Chinese liver transplant patients. 2006 , 12, 775-80			87
126	MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells. 2006 , 95, 2293-308			113
125	Single nucleotide polymorphisms in human P-glycoprotein: its impact on drug delivery and disposition. 2006 , 3, 23-35			22
124	Influence of different allelic variants of the CYP3A and ABCB1 genes on the tacrolimus pharmacokinetic profile of Chinese renal transplant recipients. <i>Pharmacogenomics</i> , 2006 , 7, 563-74	2.6		33
123	Is there an effect of food on the biliary secretion of cyclosporine and three in vivo formed metabolites in a porcine model?. 2007 , 17, 253-258			1
122	Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects. 2007 , 37, 315-27			51
121	Clinical pharmacogenetics in pediatric patients. <i>Pharmacogenomics</i> , 2007 , 8, 1403-11	2.6		16
120	Overview of pharmacogenetics. 2007 , Chapter 6, Unit6.10			
119	The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia. 2007 , 92, 308-14			61
118	Polymorphisms of multidrug resistance gene (MDR1) and cyclosporine absorption in de novo renal transplant patients. 2007 , 83, 1380-4			22
117	CYP3A5*3 and CYP3A4*1B allele distribution and genotype combinations: differences between Spaniards and Central Americans. <i>Therapeutic Drug Monitoring</i> , 2007 , 29, 412-6	3.2		27
116	The emerging importance of transporter proteins in the psychopharmacological treatment of the pregnant patient. 2007 , 39, 723-46			22
115	Cytochrome P450 3A polymorphisms and immunosuppressive drugs: an update. <i>Pharmacogenomics</i> , 2007 , 8, 835-49	2.6		77
114	Pharmacogenetics as a tool for optimising drug therapy in solid-organ transplantation. 2007 , 8, 2045-58			21
113	ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. 2007 , 7, 154-79			220

112	Multidrug resistance gene-1 polymorphisms and resistance to cyclosporine A in patients with steroid resistant ulcerative colitis. 2007 , 13, 19-23		27
111	Enaminones: Exploring additional therapeutic activities. 2007 , 96, 2509-31		70
110	The GST deletions and NQO1*2 polymorphism confers interindividual variability of response to treatment in patients with acute myeloid leukemia. 2007 , 31, 947-53		33
109	Multi-drug resistance gene-1 (MDR-1) haplotypes and the CYP3A5*1 genotype have no influence on ciclosporin dose requirements as assessed by C0 or C2 measurements. 2007 , 21, 252-7		28
108	Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. 2007 , 136, 590-6		63
107	Tacrolimus pharmacokinetics and pharmacogenetics: influence of adenosine triphosphate-binding cassette B1 (ABCB1) and cytochrome (CYP) 3A polymorphisms. 2007 , 21, 427-35		63
106	Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. <i>European Journal of Clinical Pharmacology</i> , 2008 , 64, 1069-84	2.8	72
105	No association between MDR1 (ABCB1) 2677G>T and 3435C>T polymorphism and sporadic colorectal cancer among Bulgarian patients. 2008 , 134, 317-22		32
104	Meta-analysis of the effect of MDR1 C3435T polymorphism on cyclosporine pharmacokinetics. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2008 , 103, 433-44	3.1	43
103	Association of four DNA polymorphisms with acute rejection after kidney transplantation. 2008 , 21, 879-91		87
102	Pharmacogenetics in solid organ transplantation: current status and future directions. 2008 , 22, 6-20		51
101	Genetic polymorphisms and the fate of the transplanted organ. 2008 , 22, 131-40		37
100	Genotyping with a dried blood spot method: a useful technique for application in pharmacogenetics. <i>Clinica Chimica Acta</i> , 2008 , 388, 189-91	6.2	19
99	Individualizing Therapy in Patients With Chronic Kidney Disease. 2008 , 21, 225-236		
98	Genetic Polymorphisms in Relation to Immunosuppressive Drug Pharmacokinetics in Organ Transplantation: Current Knowledge and Perspectives. 2008 , 6, 56-62		
97	Clinical pharmacogenetics and potential application in personalized medicine. <i>Current Drug Metabolism</i> , 2008 , 9, 738-84	3.5	171
96	Role of pharmacogenetics of immunosuppressive drugs in organ transplantation. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 143-50	3.2	45
95	Clinical significance of a CYP2D6 poor metabolizer--a patient with schizophrenia on risperidone treatment. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 748-51	3.2	8

94	CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 689-99	3.2	57
93	Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. <i>Pharmacogenetics and Genomics</i> , 2008 , 18, 390-402	1.9	44
92	Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome. 2008 , 85, S19-24		32
91	. 2009 ,		9
90	CYP3A polymorphisms and immunosuppressive drugs in solid-organ transplantation. 2009 , 9, 383-90		23
89	Can we personalize treatment for kidney diseases?. 2009 , 4, 1670-6		15
88	ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. 2009 , 132, 2517-30		63
87	Clinical impact of polymorphisms of transport proteins and enzymes involved in the metabolism of immunosuppressive drugs. <i>Transplantation Proceedings</i> , 2009 , 41, 1441-55	1.1	32
86	Polymorphism of human cytochrome P450 enzymes and its clinical impact. 2009 , 41, 89-295		579
85	Overview of pharmacogenetics. 2009 , Chapter 9, Unit 9.19		3
84	A single-nucleotide polymorphism in the MDR1 gene as a predictor of response to neoadjuvant chemotherapy in breast cancer. 2009 , 9, 161-5		45
83	Gender and interindividual variability in pharmacokinetics. 2009 , 41, 408-21		71
82	Pharmacogenetic testing after a simple DNA isolation method on buccal swab samples. <i>Pharmacogenomics</i> , 2009 , 10, 983-7	2.6	5
81	Incidence of genetic polymorphisms involved in lipid metabolism among Chinese patients with osteonecrosis of the femoral head. 2009 , 80, 325-9		23
80	Pharmacogenetics of calcineurin inhibitors in renal transplantation. 2009 , 88, S62-7		32
79	Genetic Polymorphisms in ABC Transporters. 411-436		
78	ATP-binding cassette subfamily B member 1 polymorphisms do not determine cyclosporin exposure, acute rejection or nephrotoxicity after heart transplantation. 2010 , 89, 75-82		11
77	Pharmacogenetics in immunosuppressants: impact on dose requirement of calcineurin inhibitors in renal and liver pediatric transplant recipients. <i>Current Opinion in Organ Transplantation</i> , 2010 , 15, 601-7	2.5	11

76	The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone. <i>European Journal of Clinical Pharmacology</i> , 2010 , 66, 1109-17	2.8	72
75	Pharmacogenomics: a new paradigm to personalize treatments in nephrology patients. 2010 , 159, 268-80		18
74	Effect of gene polymorphisms on the levels of calcineurin inhibitors in Indian renal transplant recipients. 2010 , 20, 146-51		12
73	Pharmacogenomics: bridging the gap between science and practice. 2010 , 50, e1-14; quiz e15-7		22
72	Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. <i>Clinical Pharmacokinetics</i> , 2010 , 49, 141-75	6.2	246
71	Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II. <i>Clinical Pharmacokinetics</i> , 2010 , 49, 207-21	6.2	148
70	Pharmacogenetic Analysis of Calcineurin Inhibitors in Renal Transplant Patients: Towards Personalized Immunosuppressive Therapy?. 2010 , 4, 5-14		
69	Influence of CYP3A5 and MDR1(ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in Chinese renal transplant recipients. <i>Transplantation Proceedings</i> , 2010 , 42, 3455-8	1.1	21
68	Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients. 2011 , 63, 815-25		20
67	ABC Transporters in Intestinal and Liver Efflux. 2011 , 381-400		
66	Immunosuppressants Pharmacogenomics. 2011 , 249-265		
65	Pharmacogenomic Testing in Current Clinical Practice. 2011 ,		1
64	Pharmacogenetics and Renal Transplantation. 2011 ,		
63	Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCC2 and their impact on drug disposition. 2011 , 12, 631-46		50
62	Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients. 2011 , 28, 1093-102		36
61	Interplay of pharmacogenetic variations in ABCB1 transporters and cytochrome P450 enzymes. 2011 , 34, 1817-28		13
60	Pharmacogenomics in neurology: current state and future steps. 2011 , 70, 684-97		23
59	Drug-induced cholestasis. 2011 , 53, 1377-87		236

58	MDR-1 gene polymorphisms in steroid-responsive versus steroid-resistant nephrotic syndrome in children. 2011 , 26, 3968-74		34
57	Do drug transporter (ABCB1) SNPs influence cyclosporine and tacrolimus dose requirements and renal allograft outcome in the posttransplantation period?. <i>Journal of Clinical Pharmacology</i> , 2011 , 51, 603-15	2.9	21
56	The Frequency and Association of C609T and C465T Polymorphisms of NAD(P)H:Quinone Oxidoreductase Gene With Adult Acute Myeloid Leukemia. 2011 , 42, 674-677		3
55	Association between lamotrigine concentrations and ABCB1 polymorphisms in patients with epilepsy. <i>Therapeutic Drug Monitoring</i> , 2012 , 34, 518-25	3.2	32
54	ATP-binding cassette transporters as pharmacogenetic biomarkers for kidney transplantation. <i>Clinica Chimica Acta</i> , 2012 , 413, 1326-37	6.2	25
53	Pharmacogenetics of Drug Transporters. 2012 , 101-148		2
52	Multifactorial etiology of gastric cancer. <i>Methods in Molecular Biology</i> , 2012 , 863, 411-35	1.4	102
51	Genetic contribution to variable human CYP3A-mediated metabolism. <i>Advanced Drug Delivery Reviews</i> , 2012 , 64, 256-269	18.5	19
50	Pharmacogenetics in kidney transplantation: recent updates and potential clinical applications. <i>Molecular Diagnosis and Therapy</i> , 2012 , 16, 331-45	4.5	15
49	Cancer Epigenetics. <i>Methods in Molecular Biology</i> , 2012 ,	1.4	4
48	The potential of steroids and xenobiotic receptor polymorphisms in forecasting cyclosporine pharmacokinetic variability in young kidney transplant recipients. <i>Pediatric Transplantation</i> , 2012 , 16, 658-63	1.8	12
47	ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients. <i>European Journal of Clinical Pharmacology</i> , 2013 , 69, 385-93	2.8	30
46	MDR1 polymorphisms are associated with inflammatory bowel disease in a cohort of Croatian IBD patients. <i>BMC Gastroenterology</i> , 2013 , 13, 57	3	25
45	CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. <i>Pharmacogenomics</i> , 2013 , 14, 47-62	2.6	142
44	Genes and beans: pharmacogenomics of renal transplant. <i>Pharmacogenomics</i> , 2013 , 14, 783-98	2.6	14
43	A functional common polymorphism of the ABCB1 gene is associated with chronic kidney disease and hypertension in Chinese. <i>American Journal of Hypertension</i> , 2013 , 26, 1428-36	2.3	11
42	Meta-Analysis of ABCB1 3435C>T Polymorphism and Colorectal Cancer. <i>Pakistan Journal of Medical Sciences</i> , 2013 , 29, 1269-74	2	3
41	PharmGKB summary: cyclosporine and tacrolimus pathways. <i>Pharmacogenetics and Genomics</i> , 2013 , 23, 563-85	1.9	137

40	Cytochrome P450 3A4FNx011B as pharmacogenomic predictor of tacrolimus pharmacokinetics and clinical outcome in the liver transplant recipients. <i>Saudi Journal of Gastroenterology</i> , 2013 , 19, 89-95	3	3
39	Functional G1199A ABCB1 polymorphism may have an effect on cyclosporine blood concentration in renal transplanted patients. <i>Journal of Clinical Pharmacology</i> , 2013 , 53, 827-33	2.9	7
38	Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients. <i>World Journal of Gastroenterology</i> , 2013 , 19, 9156-73	5.6	59
37	Multidrug-resistance 1 gene single-nucleotide polymorphisms do not influence long-term graft survival after kidney transplantation. <i>Transplantation Proceedings</i> , 2014 , 46, 2214-9	1.1	2
36	Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks. <i>British Journal of Clinical Pharmacology</i> , 2014 , 77, 715-28	3.8	33
35	The Influence of the CYP3A4*22 Polymorphism and CYP2D6 Polymorphisms on Serum Concentrations of Aripiprazole, Haloperidol, Pimozide, and Risperidone in Psychiatric Patients. <i>Journal of Clinical Psychopharmacology</i> , 2015 , 35, 228-36	1.7	45
34	The Effect of ABCB1 C3435T Polymorphism on Cyclosporine Dose Requirements in Kidney Transplant Recipients: A Meta-Analysis. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015 , 117, 117-23	3.1	15
33	Pharmacogenetics and drug-induced nephrotoxicity in renal transplant recipients. <i>BioImpacts</i> , 2015 , 5, 45-54	3.5	26
32	Relationship between mRNA expression levels of CYP3A4, CYP3A5 and SXR in peripheral mononuclear blood cells and aging in young kidney transplant recipients under tacrolimus treatment. <i>Pharmacogenomics</i> , 2015 , 16, 483-91	2.6	2
31	Therapeutic drug monitoring in pediatric renal transplantation. <i>Pediatric Nephrology</i> , 2015 , 30, 253-65	3.2	15
30	Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters. <i>Genome Medicine</i> , 2016 , 8, 119	14.4	6
29	Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs. <i>Therapeutic Drug Monitoring</i> , 2016 , 38 Suppl 1, S57-69	3.2	39
28	. <i>Therapie</i> , 2017 , 72, 269-284	3.8	0
27	NFATC1 genotypes affect acute rejection and long-term graft function in cyclosporine-treated renal transplant recipients. <i>Pharmacogenomics</i> , 2017 , 18, 381-392	2.6	5
26	Pharmacogenetics of immunosuppressants: State of the art and clinical implementation—recommendations from the French National Network of Pharmacogenetics (RNPGx). <i>Therapie</i> , 2017 , 72, 285-299	3.8	16
25	Personalized treatment in heart transplantation. <i>Current Opinion in Organ Transplantation</i> , 2017 , 22, 215-220	2.5	6
24	Precision monitoring of immunotherapies in solid organ and hematopoietic stem cell transplantation. <i>Advanced Drug Delivery Reviews</i> , 2017 , 114, 272-284	18.5	0
23	Single-Nucleotide Polymorphism of CYP3A5 Impacts the Exposure to Tacrolimus in Pediatric Renal Transplant Recipients: A Pharmacogenetic Substudy of the TWIST Trial. <i>Therapeutic Drug Monitoring</i> , 2017 , 39, 21-28	3.2	11

22	Influence of CYP3A and ABCB1 polymorphisms on cyclosporine concentrations in renal transplant recipients. <i>Pharmacogenomics</i> , 2017 , 18, 1503-1513	2.6	15
21	Association of CYP3A4*1B genotype with Cyclosporin A pharmacokinetics in renal transplant recipients: A meta-analysis. <i>Gene</i> , 2018 , 664, 44-49	3.8	10
20	CYP3A genotypes of donors but not those of the patients increase the risk of acute rejection in renal transplant recipients on calcineurin inhibitors: a pilot study. <i>European Journal of Clinical Pharmacology</i> , 2018 , 74, 53-60	2.8	5
19	Gene Polymorphisms of Immunosuppressants in Solid Organ Transplantation. 2018 ,		
18	Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 15-37	6.2	46
17	Modulation of expression/function of intestinal P-glycoprotein under disease states. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020 , 16, 59-78	5.5	11
16	Pharmacogenomics in Precision Medicine. 2020 ,		
15	The effect of CYP3A4 genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors in renal transplant recipients: a systematic review and meta-analysis protocol.		
14	A Systematic Review and Meta-Analysis of Pharmacogenetic Studies in Patients with Chronic Kidney Disease. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	0
13	Polymorphisms in CYP3A5, CYP3A4, and ABCB1 are not associated with cyclosporine pharmacokinetics nor with cyclosporine clinical end points after renal transplantation. <i>Therapeutic Drug Monitoring</i> , 2011 , 33, 178-84	3.2	32
12	High baseline serum total and LDL cholesterol levels are associated with MDR1 haplotypes in Brazilian hypercholesterolemic individuals of European descent. <i>Brazilian Journal of Medical and Biological Research</i> , 2005 , 38, 1389-97	2.8	41
11	Association Between CYP3A4 and CYP3A5 Genotypes and Cyclosporine Blood Levels and Doses among Jordanian Kidney Transplanted Patients. <i>Current Drug Metabolism</i> , 2019 , 20, 682-694	3.5	5
10	Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis. <i>World Journal of Gastroenterology</i> , 2006 , 12, 3636-44	5.6	106
9	Calcineurin inhibitor-induced renal allograft nephrotoxicity. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2010 , 154, 297-306	1.7	20
8	Drug-Metabolizing Enzymes and P-Glycoprotein. 2004 , 43-67		
7	?????????????????????????????????????. <i>Japanese Journal of Pediatric Nephrology</i> , 2005 , 18, 105-109	0	
6	Pharmacogenetics of Drug Transporters. <i>Drugs and the Pharmaceutical Sciences</i> , 2005 , 109-155		
5	Pharmacogenetics in Infectious Diseases. 2006 , 155-187		

- 4 Drug-Metabolizing Enzymes. **2009**, 85-117
- 3 Clinical Pharmacologic Principles and Immunosuppression. **2011**, 87-109
- 2 Pharmacogenomics of Immunosuppressants. 70-97
- 1 Pharmacogenomics of Immunosuppressants. **2020**, 83-106